Cancidas 50 mg

/ MSD

Recommended Dosing in Adult Patients [≥18 years of age]: The usual dose is 50 mg once daily (following a 70-mg loading dose for most indications). The safety and efficacy of a dose of 150 mg daily (range: 1 to 51 days; median: 14 days) have been studied in 100 adult patients with candidemia and other Candida infections. The efficacy of CANCIDAS at this higher dose was not significantly better than the efficacy of the 50-mg daily
dose of CANCIDAS. The efficacy of doses higher than 50 mg daily in the other adult patients for whom CANCIDAS is indicated is not known.
See prescribing information for full details.

Invasive aspergillosis in patients who are refractory to or intolerant of other therapies. Cancidas has not been studied as initial therapy for invasive aspergillosis. Esophageal candidiasis. Candidemia and the following candida infections: Intra-abdominal abscesses, peritonitis and pleural space infections.

Hypersensitivity to any components of this product.

Concomitant use of Cancidas with cyclosporin is not recommended unless the potential benefit outweighs the potential risk to the patient. The safety and efficacy of doses above 70 mg have not been adequately studied. Cancidas should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation.

Possible histamine-mediated symptoms have been reported in clinical studies. Fever 2.9%, infused vein complications 2.9%, nausea 2.9%, vomiting 2.9%, flushing 2.9%.

See prescribing information for full details.